PRECIGEN, INC.

PGEN ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Revenue $9.7M $3.9M $6.2M $26.9M $14.3M $32.0M $90.7M $151.2M
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $41.3M $53.1M $48.6M $404.6M
SG&A Expense $70.1M $41.3M $40.4M $137.8M
Operating Income $-110.5M $-135.0M $-99.8M $-80.0M $-111.0M $-104.5M $-171.3M $-505.6M
Operating Margin -1,141.1% -3,440.2% -1,602.5% -297.2% -777.8% -326.7% -188.8% -334.4%
Interest Expense $8.5M
Pretax Income $-250.6M $-128.0M $-96.4M $-80.0M $-111.0M $-104.5M $-171.3M $-395.9M
Income Tax Expense $3.0K $-1.8M $-458.0K $-189.0K $-160.0K $-82.0K $-930.0K $-15.4M
Net Income $-250.6M $-126.2M $-95.9M $28.3M $-92.2M $-170.5M $-322.3M $-509.3M
Net Margin -2,588.2% -3,216.2% -1,540.6% 105.2% -646.0% -533.0% -355.3% -336.9%
EPS (Basic) $-1.37 $-0.47 $-0.39 $0.14 $-0.47 $-1.02 $-2.09 $-3.93
EPS (Diluted) $-1.37 $-0.47 $-0.39 $0.14 $-0.47 $-1.02 $-2.09 $-3.93
Shares Outstanding (Basic) 313.0M 267.7M 244.5M 200.4M 197.8M 167.1M 154.1M 160.0M
Shares Outstanding (Diluted) 313.0M 267.7M 244.5M 200.4M 197.8M 167.1M 154.1M 160.0M
Dividends Per Share
← Newer Page 1 of 2 Older →